Trial Profile

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
Indications Traumatic brain injuries
Focus Therapeutic Use
Sponsors Hope Biosciences

Most Recent Events

15 Jul 2026 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
15 Jul 2026 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2027.
23 Jun 2026 According to Hope Biosciences media release, this trial has been funded by Department of Defense, which is currently enrolling in Houston and San Antonio.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com